Portola Pharmaceuticals Inc (NASDAQ:PTLA), CFO Mardi Dier sold 5,000 shares of the stock in a transaction dated Thursday, May 29th. The stock was sold at an average price of $23.00, for a total value of $115,000.00. Following the completion of the sale, the chief financial officer now directly owns 19,824 shares of the company’s stock, valued at approximately $455,952. Portola Pharmaceuticals Inc (NASDAQ:PTLA), weekly performance is -4.59%. On last trading day company shares ended up $21.83. Analysts mean target price for the company is $38.50. Portola Pharmaceuticals Inc (NASDAQ:PTLA), distance from 50-day simple moving average (SMA50) is -6.66%.
Relypsa Inc (NASDAQ:RLYP), was the target of a large increase in short interest during the month of May. As of May 15th, there was short interest totalling 963,019 shares, an increase of 52.1% from the April 30th total of 633,135 shares, StockRatingsNetwork.com reports. Approximately 4.1% of the company’s shares are sold short. Based on an average daily trading volume, of 195,785 shares, the days-to-cover ratio is currently 4.9 days. Relypsa Inc (NASDAQ:RLYP), advanced 10.88% in last trading session and ended the day on $24.77. RLYP, return on assets is -107.90%. Relypsa Inc (NASDAQ:RLYP), quarterly performance is -39.56%.
Equities research analysts at Leerink Swann initiated coverage on shares of Alder Biopharmaceuticals Inc (NASDAQ:ALDR), in a research note issued to investors on Monday, TheFlyOnTheWall.com reports. The firm set an “outperform” rating and a $26.00 price target on the stock. Leerink Swann’s target price points to a potential upside of 99.23% from the company’s current price. Alder Biopharmaceuticals Inc (NASDAQ:ALDR), shares moved up 6.67% in last trading session and was closed at $13.92, while trading in range of $13.14 – 14.37. Alder Biopharmaceuticals Inc (NASDAQ:ALDR), year to date (YTD) performance is 38.78%.
On May 19, 2014, Anthony Nolan and Pacific Biosciences of California (NASDAQ:PACB), have announced that Anthony Nolan is the world’s first stem cell registry to invest in an innovative new technology for advanced tissue typing. Pacific Biosciences of California (NASDAQ:PACB), ended the last trading day at $5.06. Company weekly volatility is calculated as 8.05% and price to cash ratio as 3.00. Pacific Biosciences of California (NASDAQ:PACB), showed a positive weekly performance of 2.85%.
Chimerix Inc (NASDAQ:CMRX), Insider M Michelle Berrey purchased 14,065 shares of Chimerix stock on the open market in a transaction dated Tuesday, May 27th. The stock was purchased at an average price of $14.22 per share, with a total value of $200,004.30. Following the completion of the acquisition, the insider now directly owns 83,271 shares in the company, valued at approximately $1,184,114. Chimerix Inc (NASDAQ:CMRX), weekly performance is 7.59%. On last trading day company shares ended up $20.99. Analysts mean target price for the company is $31.67. Chimerix Inc (NASDAQ:CMRX), distance from 50-day simple moving average (SMA50) is 7.50%.